PROCEPT BioRobotics Q4 Results Miss Estimates, Downgraded by BofA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy PRCT?
Source: stocktwits
- Disappointing Earnings: PROCEPT BioRobotics reported Q4 revenue of $76.4 million, a 12% year-over-year increase, yet fell short of analyst expectations of $93.7 million, resulting in a loss per share of $0.53, significantly worse than the anticipated $0.31, indicating ongoing financial strain.
- Downgrade Impact: Bank of America downgraded PROCEPT's rating from 'Neutral' to 'Underperform' due to profitability concerns, slashing the price target from $38 to $20, reflecting skepticism about the company's ability to meet future earnings projections amid deepening losses.
- Market Reaction: Following the earnings report, PROCEPT's stock plummeted over 28% in premarket trading, highlighting investor anxiety regarding the company's execution and financial momentum, which could hinder future fundraising efforts.
- Retail Sentiment Shift: Despite the stock's decline, retail investor sentiment on Stocktwits shifted from 'bullish' to 'extremely bullish', with message volume spiking significantly within 24 hours, suggesting some investors remain optimistic about potential recovery prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRCT
Wall Street analysts forecast PRCT stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 27.260
Low
38.00
Averages
51.75
High
65.00
Current: 27.260
Low
38.00
Averages
51.75
High
65.00
About PRCT
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PROCEPT BioRobotics Receives Overweight Rating
- Rating Upgrade: PROCEPT BioRobotics (PRCT) has received an overweight rating, indicating analysts' optimistic outlook on its future performance, which may attract more investor interest.
- Price Target Analysis: The average price target set by analysts is $42.36, reflecting a positive market expectation regarding the company's growth potential, which could drive the stock price higher.
- Market Confidence: An overweight rating typically suggests that analysts believe the stock will outperform its peers, potentially enhancing investor confidence in the company's long-term investment prospects.
- Investment Appeal: With the rating upgrade and price target set, PROCEPT BioRobotics may attract more institutional investors, thereby increasing its market liquidity and shareholder value.
See More
PROCEPT BioRobotics Reports Disappointing Earnings Guidance
- Financial Performance Overview: PROCEPT BioRobotics reported total revenue of $76.4 million in Q4 2025, a 12% increase year-over-year, but fell short of the market expectation of $94.14 million, indicating challenges in revenue growth.
- Sales Dynamics: U.S. handpiece and consumable revenue reached $34.0 million, up 16%, while system revenue remained flat at $27.6 million compared to the previous year, reflecting a disparity between product line growth potential and market demand.
- Guidance Adjustment: The company lowered its fiscal 2026 sales guidance from $410 million-$430 million to $390 million-$410 million, and while U.S. procedure growth is expected between 39% and 48%, the close alignment of handpiece sales and procedure volumes may impact revenue.
- Market Reaction and Analysis: PROCEPT BioRobotics shares fell 26.33% to $20.51 in premarket trading, nearing a 52-week low, with analysts suggesting the stock is undervalued and that the market has not adequately recognized its potential expansion into prostate cancer.
See More
PROCEPT BioRobotics Q4 Results Miss Estimates, Downgraded by BofA
- Disappointing Earnings: PROCEPT BioRobotics reported Q4 revenue of $76.4 million, a 12% year-over-year increase, yet fell short of analyst expectations of $93.7 million, resulting in a loss per share of $0.53, significantly worse than the anticipated $0.31, indicating ongoing financial strain.
- Downgrade Impact: Bank of America downgraded PROCEPT's rating from 'Neutral' to 'Underperform' due to profitability concerns, slashing the price target from $38 to $20, reflecting skepticism about the company's ability to meet future earnings projections amid deepening losses.
- Market Reaction: Following the earnings report, PROCEPT's stock plummeted over 28% in premarket trading, highlighting investor anxiety regarding the company's execution and financial momentum, which could hinder future fundraising efforts.
- Retail Sentiment Shift: Despite the stock's decline, retail investor sentiment on Stocktwits shifted from 'bullish' to 'extremely bullish', with message volume spiking significantly within 24 hours, suggesting some investors remain optimistic about potential recovery prospects.
See More
Marriott Vacations Reports Strong Q4, Shares Surge
- Earnings Beat: Marriott Vacations reported an adjusted EPS of $1.86 for Q4, surpassing market expectations of $1.57, which highlights the company's strong profitability and boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $1.323 billion, exceeding the anticipated $1.294 billion, indicating sustained competitiveness in the market and enhancing shareholder value.
- Stock Surge: In pre-market trading, Marriott Vacations shares jumped 12.7% to $65.34, reflecting market optimism about the company's future growth potential and likely attracting more investor interest.
- Positive Guidance: The company also issued FY26 adjusted EPS guidance above estimates, further solidifying its leadership position in the vacation industry and laying a strong foundation for future growth.
See More
Procept Releases Financial Guidance for FY 2026
- Disappointing Earnings Report: Procept's Q4 GAAP EPS of -$0.53 missed expectations by $0.20, indicating challenges in profitability, while revenue of $76.4 million, up 12% year-over-year, fell short of expectations by $17.3 million, reflecting insufficient market demand.
- FY 2026 Revenue Guidance: The company expects FY 2026 revenue to range between $390 million and $410 million, representing a growth of 27% to 33% compared to the prior year, demonstrating confidence in future growth despite current financial pressures.
- Procedure Growth Forecast: Projected U.S. procedure growth for FY 2026 is expected to be between 39% and 48%, indicating potential for expansion in the medical procedure sector, suggesting optimism about future market demand despite current financial performance.
- Operating Expenses and EBITDA Outlook: The company anticipates operating expenses of approximately $350 million for FY 2026, with adjusted EBITDA losses expected to range from $30 million to $17 million, indicating challenges in cost control and a cautious outlook on future profitability.
See More
High Options Volume for PROCEPT BioRobotics and Bank of America
- PROCEPT Options Volume: PROCEPT BioRobotics Corp has seen an options volume of 5,378 contracts today, equating to approximately 537,800 shares, which represents 44% of its average daily trading volume of 1.2 million shares over the past month.
- High Call Option Activity: Notably, the $30 strike call option expiring on March 20, 2026, has traded 4,733 contracts today, representing about 473,300 underlying shares, indicating strong bullish sentiment in the market for this stock.
- Bank of America Options Volume: In parallel, Bank of America Corp has recorded an options volume of 169,846 contracts today, amounting to approximately 17 million shares, which is 43.6% of its average daily trading volume of 38.9 million shares over the past month.
- High Put Option Activity: Specifically, the $50 strike put option expiring on April 17, 2026, has seen 7,181 contracts traded today, representing around 718,100 shares, reflecting market concerns regarding potential downside risks for the stock.
See More
PROCEPT BioRobotics Receives Overweight Rating
- Rating Upgrade: PROCEPT BioRobotics (PRCT) has received an overweight rating, indicating analysts' optimistic outlook on its future performance, which may attract more investor interest.
- Price Target Analysis: The average price target set by analysts is $42.36, reflecting a positive market expectation regarding the company's growth potential, which could drive the stock price higher.
- Market Confidence: An overweight rating typically suggests that analysts believe the stock will outperform its peers, potentially enhancing investor confidence in the company's long-term investment prospects.
- Investment Appeal: With the rating upgrade and price target set, PROCEPT BioRobotics may attract more institutional investors, thereby increasing its market liquidity and shareholder value.
See More
PROCEPT BioRobotics Reports Disappointing Earnings Guidance
- Financial Performance Overview: PROCEPT BioRobotics reported total revenue of $76.4 million in Q4 2025, a 12% increase year-over-year, but fell short of the market expectation of $94.14 million, indicating challenges in revenue growth.
- Sales Dynamics: U.S. handpiece and consumable revenue reached $34.0 million, up 16%, while system revenue remained flat at $27.6 million compared to the previous year, reflecting a disparity between product line growth potential and market demand.
- Guidance Adjustment: The company lowered its fiscal 2026 sales guidance from $410 million-$430 million to $390 million-$410 million, and while U.S. procedure growth is expected between 39% and 48%, the close alignment of handpiece sales and procedure volumes may impact revenue.
- Market Reaction and Analysis: PROCEPT BioRobotics shares fell 26.33% to $20.51 in premarket trading, nearing a 52-week low, with analysts suggesting the stock is undervalued and that the market has not adequately recognized its potential expansion into prostate cancer.
See More
PROCEPT BioRobotics Q4 Results Miss Estimates, Downgraded by BofA
- Disappointing Earnings: PROCEPT BioRobotics reported Q4 revenue of $76.4 million, a 12% year-over-year increase, yet fell short of analyst expectations of $93.7 million, resulting in a loss per share of $0.53, significantly worse than the anticipated $0.31, indicating ongoing financial strain.
- Downgrade Impact: Bank of America downgraded PROCEPT's rating from 'Neutral' to 'Underperform' due to profitability concerns, slashing the price target from $38 to $20, reflecting skepticism about the company's ability to meet future earnings projections amid deepening losses.
- Market Reaction: Following the earnings report, PROCEPT's stock plummeted over 28% in premarket trading, highlighting investor anxiety regarding the company's execution and financial momentum, which could hinder future fundraising efforts.
- Retail Sentiment Shift: Despite the stock's decline, retail investor sentiment on Stocktwits shifted from 'bullish' to 'extremely bullish', with message volume spiking significantly within 24 hours, suggesting some investors remain optimistic about potential recovery prospects.
See More
Marriott Vacations Reports Strong Q4, Shares Surge
- Earnings Beat: Marriott Vacations reported an adjusted EPS of $1.86 for Q4, surpassing market expectations of $1.57, which highlights the company's strong profitability and boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $1.323 billion, exceeding the anticipated $1.294 billion, indicating sustained competitiveness in the market and enhancing shareholder value.
- Stock Surge: In pre-market trading, Marriott Vacations shares jumped 12.7% to $65.34, reflecting market optimism about the company's future growth potential and likely attracting more investor interest.
- Positive Guidance: The company also issued FY26 adjusted EPS guidance above estimates, further solidifying its leadership position in the vacation industry and laying a strong foundation for future growth.
See More
Procept Releases Financial Guidance for FY 2026
- Disappointing Earnings Report: Procept's Q4 GAAP EPS of -$0.53 missed expectations by $0.20, indicating challenges in profitability, while revenue of $76.4 million, up 12% year-over-year, fell short of expectations by $17.3 million, reflecting insufficient market demand.
- FY 2026 Revenue Guidance: The company expects FY 2026 revenue to range between $390 million and $410 million, representing a growth of 27% to 33% compared to the prior year, demonstrating confidence in future growth despite current financial pressures.
- Procedure Growth Forecast: Projected U.S. procedure growth for FY 2026 is expected to be between 39% and 48%, indicating potential for expansion in the medical procedure sector, suggesting optimism about future market demand despite current financial performance.
- Operating Expenses and EBITDA Outlook: The company anticipates operating expenses of approximately $350 million for FY 2026, with adjusted EBITDA losses expected to range from $30 million to $17 million, indicating challenges in cost control and a cautious outlook on future profitability.
See More
High Options Volume for PROCEPT BioRobotics and Bank of America
- PROCEPT Options Volume: PROCEPT BioRobotics Corp has seen an options volume of 5,378 contracts today, equating to approximately 537,800 shares, which represents 44% of its average daily trading volume of 1.2 million shares over the past month.
- High Call Option Activity: Notably, the $30 strike call option expiring on March 20, 2026, has traded 4,733 contracts today, representing about 473,300 underlying shares, indicating strong bullish sentiment in the market for this stock.
- Bank of America Options Volume: In parallel, Bank of America Corp has recorded an options volume of 169,846 contracts today, amounting to approximately 17 million shares, which is 43.6% of its average daily trading volume of 38.9 million shares over the past month.
- High Put Option Activity: Specifically, the $50 strike put option expiring on April 17, 2026, has seen 7,181 contracts traded today, representing around 718,100 shares, reflecting market concerns regarding potential downside risks for the stock.
See More
